Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/09/26	ILA 162.70	+0.62%	20,098
01/09/26	ILA 161.70	-2.71%	62,621
31/08/26	ILA 166.20	+3.68%	31,324
28/08/26	ILA 160.30	-1.54%	36,058
27/08/26	ILA 162.80	-0.12%	27,700

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - TEL AVIV STOCK EXCHANGE 15:24:47 02/09/2026 BST			5-day change	1st Jan Change
162.70 ^ILa	+0.62%		-0.18%	-45.87%

08-28	L.I.A. Pure Capital Issues Response to Evogene	CI
08-25	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI

Market Cap	7.24M 0 6.25M 5.88M 5.36M 10.02M 684M 10.1M 69.67M 27.04M 350M 27.19M 26.6M 1.15B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	7.24M 0 6.25M 5.88M 5.36M 10.02M 684M 10.1M 69.67M 27.04M 350M 27.19M 26.6M 1.15B	EV / Sales 2026 *	4.88x	EV / Sales 2027 *	2.78x
Free-Float	72.14%	Yield 2026 *	-	Yield 2027 *	-

08-28	L.I.A. Pure Capital Issues Response to Evogene	CI
08-25	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI
08-18	Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026
08-18	Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-17	Freightos Names Yaron Eldad as Chief Financial Officer	MT
07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/12/20	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

Evogene Ltd. Share Price

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation : Evogene Ltd.

Chart: Evogene Ltd.

Latest news : Evogene Ltd.

Last Transcript : Evogene Ltd.

Analysts' recommendations : Evogene Ltd.

Press Releases : Evogene Ltd.

News in other languages : Evogene Ltd.

Quotes and Performance

Price Extremes

Managers and Directors : Evogene Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-31	Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward	PR
08-25	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees	PR
08-18	Evogene Reports Second Quarter and First Half 2026 Financial Results	PR
08-18	Evogene : Reports Second Quarter and First Half 2026 Financial Results	PU
08-18	Evogene: Q2 Earnings Snapshot	AQ

1 day	+0.62%
1 week	-0.18%
Current month	-2.11%
1 month	+12.05%
3 months	-4.29%
6 months	-38.28%
Current year	-45.87%

1 week	158	170
1 month	143.6	229.8
Current year	115.1	410
1 year	115.1	478.7
3 years	115.1	3,700
5 years	115.1	10,430
10 years	115.1	33,500

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	30/11/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	31/12/2021

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	02/06/2010
Sarit Firon CHM	Chairman	60	31/05/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/08/26	Leon Recanati	Buy	Director	460,000	2.9111%
04/08/26	Leon Recanati	Buy	Director	800,000	5.0628%
01/04/26	Polina Ravzin	Other	Executive/Senior Manager	20,000	0.2294%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	+0.62%	-0.18%	-61.47%	-94.27%	7.24M
LONZA GROUP AG	+0.97%	-0.75%	+3.51%	+17.79%	49.74B
REVOLUTION MEDICINES, INC.	+0.15%	-2.71%	+430.22%	+522.13%	44.98B
IQVIA HOLDINGS INC.	+2.68%	+1.63%	+44.65%	+20.32%	42.52B
BEONE MEDICINES AG	+0.87%	-3.68%	+9.02%	+76.71%	40.78B
CELLTRION, INC.	-0.90%	-1.74%	+15.20%	+48.44%	32.89B
ASCENDIS PHARMA A/S	+2.26%	+6.19%	-	-	17.09B
MEDPACE HOLDINGS, INC.	+1.46%	-4.51%	+24.88%	+122.97%	16.28B
EUROFINS SCIENTIFIC SE	+1.70%	-0.05%	+18.53%	+28.09%	14.4B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.68%	-1.78%	+79.76%	+41.88%	13.48B
Average	+1.24%	-2.61%	+62.70%	+87.12%	27.22B
Weighted average by Cap.	+1.08%	-2.25%	+94.25%	+129.09%

	2026 *	2027 *
Net sales	1.48M 0 1.28M 1.21M 1.1M 2.05M 140M 2.07M 14.28M 5.54M 71.67M 5.57M 5.45M 235M	2.6M 0 2.24M 2.11M 1.93M 3.6M 246M 3.63M 25.02M 9.71M 126M 9.76M 9.55M 413M
Net income	-16.69M -0 -14.4M -13.56M -12.36M -23.1M -1.58B -23.27M -161M -62.31M -806M -62.66M -61.29M -2.65B	-13.92M -0 -12M -11.31M -10.3M -19.26M -1.31B -19.4M -134M -51.96M -672M -52.25M -51.11M -2.21B
Net Debt	-	-